Recent Company News

• 07:46 AM ET Mar 05, 2026
  

  Can-Fite BioPharma expects to complete the previously disclosed immediate exercise of certain outstanding warrants on or ~ 5-Mar - 6-K (801.00a, -679.00)

• 10:27 AM ET Mar 04, 2026
  

  Can-Fite BioPharma announces exercise of warrants for ~$4.0M in gross proceeds (1530.00a, +794.00)

• 09:46 AM ET Mar 04, 2026
  

  Can-Fite BioPharma halted; news pending ($10.40, +5.40)

• 07:03 AM ET Mar 04, 2026
  

  Can-Fite BioPharma's namodenoson successfully meets primary endpoint in Phase 2a pancreatic cancer study (775.00a, +39.00)

• 07:01 AM ET Feb 17, 2026
  

  Can-Fite BioPharma announced the publication of a peer-reviewed study in the International Journal of Obesity demonstrating the anti-obesity effect of namodenoson, the company's lead drug candidate. (692.00a, +12.00)

• 07:05 AM ET Feb 09, 2026
  

  Can-Fite BioPharma receives Canadian patent allowance for Namodenoson as an anti-obesity therapy (674.00a, +13.00)

• 07:03 AM ET Feb 05, 2026
  

  Can-Fite BioPharma announces that a patient with advanced decompensated liver cirrhosis who was treated with Namodenoson (670.00a, +13.00)

• 07:03 AM ET Jan 20, 2026
  

  Can-Fite BioPharma completes patient enrollement in its Phase 2a pancreatic cancer clinical trial of Namodenoson (680.00a, 0.00)

• 07:01 AM ET Dec 26, 2025
  

  Can-Fite granted Brazilian patent for treatment of sexual dysfunction ($0.18, 0.00)

• 12:07 PM ET Dec 24, 2025
  

  Can-Fite BioPharma downgraded to hold from buy at D. Boral Capital ($0.17, -0.07)